Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nutripharmaceuticals for osteoarthritis
Autore:
Hauselmann, HJ;
Titolo Testata:
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
fascicolo: 4, volume: 15, anno: 2001,
pagine: 595 - 607
SICI:
1521-6942(200110)15:4<595:NFO>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
ORAL CHONDROITIN SULFATE; KNEE OSTEOARTHRITIS; ARTICULAR-CARTILAGE; DOUBLE-BLIND; GLUCOSAMINE HYDROCHLORIDE; HERBAL MEDICINE; FOLLOW-UP; EFFICACY; MANAGEMENT; PROGRESSION;
Keywords:
osteoarthritis (OA); glucosamine-sulphate; chondroitin-sulphate; nutraceuticals; avocado/soybean; vitamin C; vitamin D; vitamin E; folic acid; zinc; selenium; manganese; copper; oligo-elements;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
45
Recensione:
Indirizzi per estratti:
Citazione:
H.J. Hauselmann, "Nutripharmaceuticals for osteoarthritis", BEST PR R C, 15(4), 2001, pp. 595-607

Abstract

What is the level of evidence for current symptomatic agents (SYSADOA) in patients with osteoarthritis? Existing publications which met the inclusioncriteria were rated by calculating the effect size of the compounds and applying a quality assessment score of the study methodology. This produced amedian effect size for the primary outcome measure, pain, of 1.37 (range 0.37-1.50) for chondroitin-sulphate and 0.57 (range 0.26-1.02) for glucosamine-sulphate in patients with knee osteoarthritis. These effect sizes were strongly diminished when only recent high-quality studies were considered (effect size of pain for chondroitin-sulphate 0.37 and for glucosamine-sulphate 0.26). Effect sizes for functional improvement and overal WOMAC index (pain, stiffness and function) were in the same range for both compounds. So far, and in contrast to recent claims, there is no reliable scientific evidence that these two substances have structure-modifying actions with respect to prohibiting, healing or restoring cartilage lesions. There is only scarce or no scientific evidence for the effects of nutrients in patients withknee, hip or hand osteoarthritis. Several large company-sponsored and independent trials with several of these nutripharmaceuticals are ongoing in Europe and the USA.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 09:51:18